Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

November 5, 2026

To
Listing / Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

BSE CODE: 543329

To
Listing / Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE SYMBOL: WINDLAS

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting held on November 5, 2026

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), as amended from time to time, please be informed that the Board of Directors of the Company, at its meeting held today, inter alia, considered and approved, the following:

1. **Financial Results**

   The Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026, prepared in accordance with the Indian Accounting Standards (Ind AS), were considered, approved and taken on record. A copy of the said Financial Results together with the Limited Review Report issued by M/s J C Bhalla & Co, Statutory Auditors of the Company, is enclosed as **Annexure I**.

2. **Resignation from the position of Whole-time Director and Directorship of the Company**

   The Board has noted and accepted the resignation of Mr. Ashok Kumar Windlass (DIN: 00011451) from the position of Whole-time Director and Director of the Company with effect from November 5, 2026 at 10.00 A.M, due to the Company's long-term succession planning. Consequently, he shall also cease to be a Member of Corporate Social Responsibility Committee of the Company. The letter of resignation received from Mr. Ashok Kumar Windlass is enclosed as **Annexure II.**

3. **Appointment of Senior Management Personnel**

   Based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, the Board of Directors has approved the appointment of Mr. Ashok Kumar Windlass, Founder President, as Senior Management Personnel of the Company, effective from November 6, 2026, subject to the approval by the shareholders of the Company.

4. **Appointment of Chairman of the Board of Directors**

   The Board of Directors has approved the appointment of Mr. Hitesh Windlass (DIN: 02030941), Managing Director and Promoter of the Company as the Chairman of the Board with effect from November 5, 2026.

The details as required under Regulation 30 read with Para A of Schedule III (Part A) of the Listing Regulations, along with the additional details required under the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026, on continuous disclosure requirements, relating to aforesaid appointments are annexed as **Annexure III**.

Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

The meeting of the Board of Directors commenced at 2.30 P.M. and concluded at 3.35 P.M.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Windlas Biotech Limited

ANANTA NARAYAN PANDA
2026.11.05 15:55:49 +05'30'
11.0.10

Ananta Narayan Panda
Company Secretary & Compliance Officer

Encl: as above

J C BHALLA & CO.
CHARTERED ACCOUNTANTS

Annexure I

BRANCH OFFICE : B-5, SECTOR-6, NOIDA - 201 301 (U.P.)
TEL. : +91 - 120 - 4241000, FAX : +91-120-4241007
E-MAIL : taxaid@jcbhalla.com

Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Windlas Biotech Limited

1. We have reviewed the accompanying statement of unaudited financial results of Windlas Biotech Limited ("the Company") for the quarter and six months ended September 30, 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended'

2. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. The preparation of the statement is in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Indian Accounting Standards (Ind-AS)- prescribed under section 133 of the Companies Act,2013, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

J C BHALLA & CO. Chartered Accountants

5. **Other Matter**

We draw attention to Note 9 to the accompanying Statement, which states that pursuant to the filing for dissolution of Windlas Inc., USA, a wholly owned non-operating subsidiary of the Company, with the Delaware Division of Corporations and pursuant to the Board Resolution dated February 5, 2026, the said subsidiary stands dissolved with effect from March 31, 2026. Accordingly, with effect from April 1, 2026, the Company is no longer required to prepare consolidated financial statements.
Our conclusion is not modified in respect of this matter.

For **J C Bhalla & Co.**
Chartered Accountants
Firm Regn. No. - 001111N

J C BHALLA & CO. Chartered Accountants

Anshuman Mallick
Partner
Membership No. - 547705
UDIN: 26547705NWZPA48987

Place: Noida
Date: November 05, 2026

Windlas Biotech Limited
CIN: L74899UR2001PLC033407
Registered office: 40/1 Mohabewala Industrial Area, SBI Road,Dehradun-248110 (Uttarakhand), India
Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| Website: www.windlasbiotech.com
Statement of unaudited financial results for the quarter and six months ended 30th September'2026
(All amounts in Indian Rupees in millions, unless otherwise stated)

Particulars	Quarter Ended			Six months ended		Year Ended
	30th September, 2026 (Unaudited)	30th June, 2026 (Unaudited)	30th September, 2025 (Unaudited)	30th September, 2026 (Unaudited)	30th September, 2025 (Unaudited)	31st March, 2026 (Audited)
Revenue from Operations	2,639.08	2,480.99	2,223.98	5,120.07	4,324.88	9,040.89
Other Income	38.61	51.13	36.45	89.74	88.84	178.04
Total Income	**2,677.69**	**2,532.12**	**2,260.43**	**5,209.81**	**4,413.72**	**9,218.93**
Expenses						
Cost of Material Consumed	1,841.71	1,687.41	1,442.87	3,529.12	2,697.41	5,501.30
Changes in Inventories of Finished goods and Work-in-progress	(218.14)	(160.12)	(73.35)	(378.26)	(30.59)	71.04
Employee Benefit Expenses	478.14	444.34	364.45	922.48	686.76	1,520.93
Finance Cost	23.34	16.50	10.16	39.84	20.73	48.25
Depreciation and Amortization expenses	75.92	72.06	75.97	147.98	150.45	307.43
Other Expenses	243.72	242.57	204.45	486.29	420.50	900.67
Total Expenses	**2,444.69**	**2,302.76**	**2,024.55**	**4,747.45**	**3,945.26**	**8,349.62**
Profit before tax	**233.00**	**229.36**	**235.88**	**462.36**	**468.46**	**869.31**
Income tax expense						
Current tax	49.10	63.54	58.76	112.64	114.29	206.99
Deferred Tax	3.38	(10.71)	(0.88)	(7.33)	(0.48)	(2.03)
Total Tax Expense	52.48	52.83	57.88	105.31	113.81	204.96
Profit for the year	**180.52**	**176.53**	**178.00**	**357.05**	**354.65**	**664.35**
Other Comprehensive Income						
(i) Items that will not be reclassified to profit or loss:						
Remeasurement of defined benefit plans- gain/(loss)	(5.97)	(0.61)	(2.33)	(6.58)	(1.85)	1.49
Income tax effect	1.51	0.15	0.59	1.66	0.47	(0.38)
Other Comprehensive Income for the year	**(4.46)**	**(0.46)**	**(1.74)**	**(4.92)**	**(1.38)**	**1.11**
Total Comprehensive Income for the year	**176.06**	**176.07**	**176.26**	**352.13**	**353.27**	**665.46**
Paid up equity share capital (Face value of Rs. 5/- per share)	103.18	103.18	105.39	103.18	105.39	105.53
Total Reserves	-	-	-	-	-	**5,702.80**
Earnings per share*:						
Basic (in Rs.)	8.75	8.46	8.48	17.21	16.91	31.59
Diluted (in Rs.)	8.56	8.32	8.40	16.84	16.72	31.14
Face value per share (in Rs)	5.00	5.00	5.00	5.00	5.00	5.00

*EPS are not annualised

Notes :

1. The unaudited financial results of the company for the six months ended on 30th September, 2026 has been prepared as per regulation 33 of the SEBI LODR (Listing Obligation and Disclosure Requirements) regulation 2015.

2.The financial results have been reviewed by the audit committee and approved by the board of directors at their meeting held on 5th November, 2026 and limited review has been carried out by statutory auditors.

3.The financial results have been prepared in accordance with the Indian Accounting Standards notified under section 133 of the companies act, 2013, read with the companies (Indian accounting standards) Rules, 2015, as amended.

4. According to Indian Accounting Standard (Ind-AS) 108 on “Operating Segment” the Company has only one primarily reportable segment i.e. "Pharmaceuticals"

5. During the period, the Company granted 21,250 units under the WBL Plan 2025 and 14,125 options under the ESOS Scheme 2023 on 21st May, 2026, at exercise prices of Rs. 5 per unit and Rs. 600 per option, respectively. In the previous year, on 15th September, 2025, the Company granted 570,500 units under the WBL Plan 2025 at an exercise price of Rs. 5 per unit.
During the previous year, the Company allotted 146,918 equity shares of face value Rs. 5 each to eligible employees pursuant to its employee stock option schemes, resulting in an increase in the issued share capital from Rs. 104.80 million to Rs. 105.53 million.
The Company recognized employee share-based payment expense of Rs. 140.58 million for the six months ended on 30th September, 2026 (year ended 31st March, 2026: Rs. 166.11 million).

6. Pursuant to the Board Resolution dated 17th April, 2026, the Company completed the buyback of 470,000 fully paid-up equity shares through the Tender Offer route at a price of Rs. 1,000 per share, aggregating to Rs. 470,000,000. Consequently, the issued, subscribed and paid-up equity share capital of the Company stands reduced to 20,636,229 equity shares of face value Rs. 5 each. The Company has created Capital Redemption Reserve amounting to INR 2.35 millions, equivalent to the nominal value of the shares bought back from securities premium.

7. The Government of India has consolidated various labour legislations into four labour codes, namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the “Codes”). The Codes became effective from 21st November, 2025. Based on the assessment performed by the company and the information presently available, including the draft rules, clarifications and guidance issued by the relevant authorities and the Institute of Chartered Accountants of India, the company has concluded that the impact of the Codes on its financial statements for the year ended 31st March, 2026 is not material. The company will continue to monitor developments relating to the implementation of the Codes and the notification of Central and State Rules and will recognise the impact, if any, in the period in which the same can be reasonably estimated.

8. The Board of Directors at its meeting held on 21st May, 2026, had proposed dividend of Rs. 6.30 Per share for the year ended 31st March, 2026. The shareholders in the annual general meeting held on 23rd July, 2026 have approved the same. The aggregate dividend payout to shareholders amounted to Rs. 130.01 million paid on 31st July, 2026.

9. Pursuant to the filing for dissolution of Windlas Inc., USA (a wholly owned non-operating subsidiary) with the Delaware Division of Corporations vide Board Resolution dated 5th February, 2026 of the Company, the said subsidiary stands dissolved with effect from 31st March, 2026. Hence, the Company's consolidated financial statements are not being prepared w.e.f. 01st April, 2026.

10. The figures for the quarter ended September 30, 2026 are the balancing figure between the unaudited figures in respect of the period ended September 30, 2026 and the published unaudited figures for the three months ended June 30, 2026, which were subject to a limited review by the statutory auditors.

For and on behalf of the board of directors of Windlas Biotech Limited




Hitesh Windlass
Managing Director
DIN: 02030941

Place: Gurugram
Date: November 5, 2026

Windlas Biotech Limited
CIN: L74899UR2001PLC033407
Registered office: 40/1 Mohabewala Industrial Area, SBI Road,Dehradun-248110 (Uttarakhand), India
Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| Website: www.windlasbiotech.com
Statement of Assets & Liabilities as on 30th September'2026
(All amounts in Indian Rupees in millions, unless otherwise stated)

Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	2,161.66	1,871.84
Capital work in Progress	-	561.55
Right of Use assets	578.47	226.67
Other Intangible Assets	28.99	34.74
Intangible Assets Under Development	28.15	34.37
Financial Assets:		
(i) Other Financial Assets	68.59	62.79
Deferred Tax Assets (Net)	13.47	4.48
Other Non-Current Assets	7.48	8.53
	2,886.81	**2,804.97**
Current Assets		
Inventories	1,133.22	618.24
Financial Assets:		
(i) Investments	2,599.36	2,683.71
(ii) Trade Receivables	2,886.35	2,274.01
(iii) Cash and Cash Equivalents	9.70	5.26
(iv) Bank Balance other than cash and cash equivalents	13.41	12.79
(v) Other Financial Assets	60.91	96.04
Current Tax Assets (Net)	-	-
Other Current Assets	563.60	578.37
	7,266.55	**6,268.42**
Total assets	**10,153.36**	**9,073.39**
EQUITY AND LIABILITIES		
Equity		
(i) Equity Share Capital	103.18	105.53
(ii) Other Equity	5,587.88	5,702.80
	5,691.06	**5,808.33**
Non-Current Liabilities		
Financial Liabilities:		
(i) Lease liability	37.66	21.48
(ii) Other Financial Liabilities	1.00	1.00
Provisions	39.43	33.32
	78.09	**55.80**
Current Liabilities		
Financial Liabilities:		
(i) Borrowings	462.38	298.75
(ii) Trade Payables		
(a) total outstanding dues of micro enterprises and small enterprises	391.82	262.98
(b) total outstanding dues for creditors other than micro enterprises and small enterprises	2,794.85	2,121.95
(iii) Lease liability	34.25	32.19
(iv) Other Financial Liabilities	536.19	401.22
Other Current Liabilities	75.44	51.13
Provisions	33.69	18.12
Current Tax Liabilities (Net)	55.59	22.92
	4,384.21	**3,209.26**
Total equity and liabilities	**10,153.36**	**9,073.39**

For and on behalf of the board of directors of Windlas Biotech Limited



Hitesh Windlass
Managing Director
DIN: 02030941

Place: Gurugram
Date: November 5, 2026

Windlas Biotech Limited
CIN: L74899UR2001PLC033407
Registered office: 40/1 Mohabewala Industrial Area, SBI Road,Dehradun-248110 (Uttarakhand), India
Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| Website: www.windlasbiotech.com
Statement of Cash Flow for the half year ended 30th September'2026
(All amounts in Indian Rupees in millions, unless otherwise stated)


Particulars	For the period ended September, 2026	For the period ended September, 2025
Cash flow from operating activities		
Profit before tax	**462.36**	**468.46**
Adjustments for:		
Depreciation & amortization expense	147.98	150.45
Allowance for Doubtful Debts	1.50	-
(Gain) / Loss on Investments measured at FVTPL	(80.74)	(77.96)
ESOP Expense	140.58	19.35
Unrealised foreign exchange (gain)/ loss	(4.72)	(5.77)
Interest expense on borrowings	37.25	18.25
Interest expense on lease liability	2.59	2.48
Interest income	(4.58)	(5.33)
Operating Profit before working capital changes	**702.22**	**569.93**
Changes in operating assets and liabilities:		
Increase/(decrease) in provisions	20.02	9.52
Increase/(decrease) in trade payables	801.74	256.99
Increase/(decrease) in other financial liabilities	147.19	67.06
Increase/(decrease) in other current liabilities	24.31	(68.85)
Decrease/(increase) in trade receivables	(609.12)	(303.29)
Decrease/(increase) in inventories	(514.98)	110.84
Decrease/(increase) in other financial assets	28.61	(3.73)
Decrease/(increase) in other non current assets	-	(0.67)
Decrease/(increase) in other current assets	14.77	(8.11)
Cash generated from operations	**614.76**	**629.69**
Income taxes refunded/ (paid)	(79.97)	(70.79)
Net cash flow from operations (A)	**534.79**	**558.90**
Cash flow from investing activities		
Purchase of property, plant & equipment, Intangible assets and capital work in progress including capital advances and capital creditors	(198.13)	(293.54)
Proceeds from redemption/ (investment in) Mutual Funds (net)	165.09	(143.91)
Interest received	5.95	5.32
Proceeds from redemption of fixed deposits	(90.61)	(50.88)
Investment in fixed deposits	89.35	45.73
Net cash used in investing activities (B)	**(28.35)**	**(437.28)**
Cash flow from financing activities		
Proceeds/(Repayment) of Short Term Borrowings	163.63	(12.23)
Proceeds from issue of equity shares through ESOP	-	32.47
Buyback of equity shares	(479.97)	-
Dividend Paid	(130.01)	(121.56)
Repayment of Lease liabilities (principal portion)	(15.81)	(1.65)
Interest on borrowings	(37.25)	(18.25)
Interest on lease liability	(2.59)	(2.48)
Net cash flow from/ (used in) financing activities (C)	**(502.00)**	**(123.70)**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	**4.44**	**(2.08)**
Cash and cash equivalents at the beginning of the year	5.26	4.20
Cash and cash equivalents at the closing of the year	**9.70**	**2.12**

Windlas Biotech Limited
CIN: L74899UR2001PLC033407
Registered office: 40/1 Mohabewala Industrial Area, SBI Road,Dehradun-248110 (Uttarakhand), India
Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| Website: www.windlasbiotech.com
Statement of Cash Flow for the half year ended 30th September'2026
(All amounts in Indian Rupees in millions, unless otherwise stated)

Notes:
a) Cash and Cash Equivalents included in Cash Flow Statement comprise of following:

Particulars	**For the period ended September, 2026**	**For the period ended September, 2025**
Balances with Banks	6.80	1.72
Fixed deposits with original maturity of less than 3 months	2.67	0.22
Cash on Hand	0.23	0.18
Total	**9.70**	**2.12**

For and on behalf of the board of directors of Windlas Biotech Limited



Hitesh Windlass
Managing Director
DIN: 02030941

Place: Gurugram
Date: November 5, 2026

Date: November 5, 2026

To
The Board of Directors
Windlas Biotech Limited
40/1, Mohabewala Industrial Area,
Dehradun -248 110
Uttarakhand, India

Dear Sir/ Madam,

Subject: Resignation from the position of Whole-time Director and Directorship of the Company

I, Ashok Kumar Windlass (DIN: 00011451), hereby tender my resignation from the position of Whole-time Director and from the Directorship of Windlas Biotech Limited ("Company") with effect from November 5, 2026 at 10.00 A.M.

As part of the Company's long-term succession planning and considering my desire to step down from the Board, I have decided to relinquish my position as Whole-time Director and Director of the Company.

I confirm that there are no other material reasons for my resignation other than those stated above.

I would like to place on record my sincere gratitude to the Board of Directors for the trust, confidence and support extended to me during my tenure. It has been a privilege and honour to serve the Company and contribute to its growth and development over the years.

I also extend my appreciation to my fellow Directors, the management team and all employees of the Company for their cooperation and support throughout my association with the Company.

I take this opportunity to convey my best wishes for the continued growth, success and prosperity of the Company and wish the Company and the Board the very best for the future.

You are requested to take this letter on record and complete all necessary formalities, including filing of the requisite forms and intimations with the concerned regulatory authorities and stock exchanges.

Thanking you,

Yours faithfully,

Ashok Kumar Windlass
DIN: 00011451

Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

Annexure III

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

S.No.	Particulars	Information with regard to Resignation of Mr. Ashok Kumar Windlass	Information with regard to appointment of Mr. Ashok Kumar Windlass	Information with regard to appointment of Mr. Hitesh Windlass
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation: The Board of Directors of the Company accepted and took on record the resignation of Mr. Ashok Kumar Windlass (DIN: 00011451) from the position of Whole-time Director and Director of the Company with effect from November 5, 2026 at 10.00 A.M, vide his resignation letter dated November 5, 2026, submitted as part of the Company's long-term succession plan.	Appointment: Based on the recommendation of the Nomination and Remuneration Committee, and Audit Committee, the Board of Directors of the Company approved the appointment of Mr. Ashok Kumar Windlass as Founder President (Senior Management Personnel) with effect from November 6, 2026, subject to approval of the shareholders since the appointment of Mr. Ashok Kumar Windlass as Founder President would constitute an appointment to an office or place of profit in the Company under Section 188(1)(f) of the Companies Act, 2013.	Appointment: The Board of Directors has appointed Mr. Hitesh Windlass (DIN: 02030941), to act as a Chairman of the Board, in addition to his current role as a Managing Director.
2.	Date of appointment/ ~~re-appointment~~/cessation & term of appointment/~~re-appointment~~	Cessation from the positions of Whole-time Director and Director of the Company with effect from November 5, 2026 at 10.00 A.M. Consequently, he ceases to be a member of Corporate Social Responsibility Committee of the Company.	November 6, 2026 Mr. Ashok Kumar Windlass has been appointed for fixed remuneration of Rs. 1,56,00,000/- (Rupees One Crore Fifty Six Lacs only) per annum i.e without any increase over the last remuneration drawn by him as Whole-time director of the Company,	Effective November 5, 2026

			considering his extensive institutional knowledge, strategic insight, industry expertise and leadership capabilities, which are expected to continue to benefit the Company.	
3.	Brief Profile (in case of appointment)	Not Applicable.	Mr. Ashok Kumar Windlass, Promoter and Founder of our Company, holds a diploma in Civil Engineering from Government Polytechnic, Ambala City. With an extensive career spanning over 56 years in the manufacturing and pharmaceutical industries in India, he has played a pivotal role in the Company's growth and development. He was appointed as Managing Director on April 1, 2001, and later took on the role of Whole-time Director on May 3, 2021. Mr. Windlass has made valuable contributions across key functions including administration, legal, and engineering.	Mr. Hitesh Windlass aged about 49 years is the Managing Director of our Company. He holds a Bachelor's degree in ceramic engineering from the Indian Institute of Technology, Banaras Hindu University and a Master's Degree in Business Administration from the Graduate School of Business, University of Chicago. He has set up our Domestic Trade Generics, OTC Brands and Exports SBVs and plays a significant role in driving the technical operations, quality, R&D, manufacturing strategy and financial strategy of our Company. He has over 18 years of experience in the field of management. He was previously associated as a process engineer with Intel Corporation, USA. He joined our Company on January 21, 2008. He is the Managing Director of our Company since April 30, 2020.
4.	Disclosure of relationships between Directors (in case of appointment of a director)	Not Applicable	Mr. Ashok Kumar Windlass is the father of Mr. Hitesh Windlass, Managing Director of the Company, and Mr. Manoj Kumar Windlass, Joint Managing Director.	Mr. Hitesh Windlas is son of Mr. Ashok Kumar Windlass (Promoter) and brother of Mr. Manoj Kumar Windlass (Joint Managing Director) and husband of Mrs. Prachi Jain Windlass.

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

			Mrs. Prachi Jain Windlass, Non-Executive Director is the daughter in law of Mr. Ashok Kumar Windlass.	
5.	Shareholding, if any, in the Company	44,00,000	44,00,000	03
6.	Confirmation w.r.t. debarment from holding the office of Director (in case of appointment of director)	Not Applicable	Not Applicable	Not debarred from holding office by virtue of any order of SEBI or any other authority.